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A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has been proposed to reduce
the risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of this systematic review was to answer
the question: Is high-dose AR drug holiday, at the time of tooth extraction or dentoalveolar surgery, necessary to
prevent the development of MRONJ in patients with cancer? This protocol was registered in the PROSPERO
database. Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for
relevant studies up to and including April 2019. Randomized controlled trials (RCTs), cohort and cross-sectional
studies, surveys, and case reports with more than five patients were included. Records were imported into www
.covidence.org. Electronic searches were supplemented by manual searches and reference linkage. The Preferred
Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) were followed. Although only one study
fitted the population, intervention, comparison, outcome (PICO) framework, valuable information on AR drug
holiday could be extracted from 14 of 371 reviewed articles. Among these, 3 were prospective and 11 were
retrospective studies. These studies described or evaluated high-dose AR drug holidays. In 2 studies, patients were
being treated with denosumab, but neither showed that a drug holiday was effective. The remaining 12 studies
evaluated bisphosphonate treatment and 2 of these studies found no reason to use AR drug holiday before surgery.
Three studies recommended drug holidays, whereas most of the studies recommended assessing each patient
separately. The only paper that fitted the PICO approach was a non-randomized, prospective study with a control
group. This study concluded that drug holiday was not necessary. Thus, there are no evidence for using drug
holiday, but it is also clear that caused by a limited numbers of eligible patients, and a great variation in between
these patient, high-level evidence for using AR drug holiday is almost impossible to obtain.1. Introduction
A considerable number of adults worldwide are treated using anti-
resorptive (AR) agents, including bisphosphonates (BPs) and denosumab.
AR agents affect bone remodeling and are used to treat osteoporosis,
metastatic bone cancer, and multiple myeloma [1, 2]. Treatment with
high-dose denosumab or Zoledronic acid delays the onset of
skeletal-related events (SREs) including fractures, lowers the risk of
subsequent SREs and reduces pain in patients with cancer and bone
metastases [2].Ottesen).
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A well-known serious adverse event of AR therapy is medication-
related osteonecrosis of the jaw (MRONJ) [1]. The American Associa-
tion of Oral and Maxillofacial Surgeons (AAOMS) defines MRONJ as an
exposed area of bone, or bone that can be probed through an intra- or
extra oral fistula that has persisted for more than eight weeks, in a
non-irradiated jaw of a patient treated with AR or antiangiogenic agents.
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bone or bone that can be probed through a fistula without subjective
symptoms. Stage II is when patients feel pain, and stage III is when pa-
tients experience severe pain and have extensive necrotic bone devel-
opment [1]. The risk of MRONJ developing depends on the frequency of
administration of AR agents (osteoporosis versus cancer), the dose per
administration (low versus high) and the duration of treatment (short
versus long). Consequently, patients with cancer who are being treated
with high doses of AR agents are at greater risk [2].
The etiology and pathogenesis of MRONJ is not completely under-
stood, but several risk factors have been identified. Numerous studies
have concluded that tooth extraction is the most important independent
risk factor for the onset of MRONJ [1, 3, 4, 5, 6]. Therefore, patients
being treated with high doses of AR agents are advised to avoid tooth
extractions if possible [1]. If a tooth extraction is absolutely necessary, a
temporary AR discontinuation in treatment, termed a ‘drug holiday’, is
recommended or considered [1]. In some countries, a drug holiday is
recommended by national guidelines or position papers based on expert
opinions [7, 8, 9, 10, 11, 12, 13], but no international consensus
regarding high-dose AR drug holidays has been reached and a systematic
review evaluating the evidence for using AR drug holiday are missing.
Current guidelines/position papers are summarized in Table 1 [1,7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18].
This systematic review has the aim to investigate the evidence and
efficacy of discontinuing high-dose AR therapy in relation to oral surgery.
Thus, the hypothesis of the review is that high-dose AR drug holiday will
reduce the risk of MRONJ.
2. Material and methods
In April 2018 a detailed protocol was written and registered online in
the PROSPERO (International Prospective Register of Systematic Re-
views) database; PROSPERO ID: 103124; registration number:
CRD42018103124 [19]. The protocol and this systematic review fol-
lowed the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [20].
2.1. Focused question
At present, most patients undergoing high-dose AR therapy are
advised to avoid dentoalveolar surgery or tooth extraction if possible. If
an extraction is required, a temporary discontinuation of AR treatment
prior to tooth extraction should be considered [1]. However, no evidence
has been collected to evaluate the efficacy of high-dose AR drug holidays
at the time of oral surgery. Therefore, we used the population, inter-
vention, comparison, outcome (PICO) framework to develop the
following focused question:
“Is a high-dose AR drug holiday at the time of tooth extraction, or
other dentoalveolar surgery, necessary to prevent the development of
MRONJ in patients with cancer?”
The PICO framework was defined as follows:
(P) Population: Adults with malignant bone disease undergoing high-
dose* AR therapy.
(I) Intervention: Discontinuation (i.e., drug holiday) of high-dose AR
therapy at the time of tooth extraction or dentoalveolar surgery.
(C) Comparison: Continuation (i.e., no drug holiday) of high-dose AR
therapy at the time of (prior to and/or after) tooth extraction or
dentoalveolar surgery.
O) Outcome: Primary outcome is development of MRONJ (þ/-) and
thereafter divided into the 4 stages of MRONJ defined by AAOMS.2*High-dose is defined as monthly treatment with i.v. BP, daily
treatment with oral ibandronic acid (Bondronate), or monthly treatment
with subcutaneous denosumab (Xgeva) [1].
2.2. Inclusion and exclusion criteria
Randomized controlled trials (RCTs), cohort and cross-sectional
studies were included. Surveys and case reports with more than five
patients were also included if they included patients being treated with
high doses of ARs (e.g., groups of patients, some being treated with low
and some with high doses of ARs). All studies referring to the focused
question (Is a high-dose AR drug holiday necessary to prevent the develop-
ment of MRONJ in patients with cancer) were included.
In vitro studies, conference abstracts, and animal studies were
excluded from the analysis.
2.3. Search strategy
The following online databases were searched:
 Medline (PubMed)
 Embase
 Cochrane Central Register of Controlled Trials (CENTRAL)
We searched for clinical studies and manuscripts published from 1
January 1990 until and including April 2019. The search was limited to
English language articles. An additional search was performed by
screening the reference lists of all the relevant full-text articles obtained.
The same search terms were used for all three databases.
The search strategy involved a combination of MeSH (Medical Sub-
ject Headings) terms and free text. MeSH terms and PubMed entry terms
were examined to identify synonyms. A separate search was performed
for each PICO element (population, intervention, comparison, and
outcome). Finally, all searches were combined in one complete search:
Search (((((((malignant bone disease) OR (breast neoplasms OR
breast tumor OR breast tumors OR breast cancer)) OR (prostate cancer
OR metastatic prostate cancer OR prostatic neoplasms OR prostatic
cancer)) OR (myelomatosis ORmultiple myelomas ORmultiple myeloma
OR myelomatosis))) AND ((((((antiresorptive drug holiday) OR (anti-
resorptive agents OR antiresorptive agent OR antiresorptive drugs OR
antiresorptive drug)) OR (diphosphonates OR bisphosphonates OR
bisphosphonate)) OR bone density conservation agents) OR (alendronate
OR zometa OR fosamax OR pamifos OR xgeva OR zoledronic acid OR
denosumab[all])) OR (discontinue OR break OR suspension OR inter-
ruption OR cessation OR time out))) AND (tooth extraction OR tooth
extractions OR extraction OR extractions OR oral surgical procedures OR
alveolectomy)) AND (bisphosphonate-associated osteonecrosis of the jaw
OR osteonecrosis OR jaw OR jaws OR ONJ OR medication related
osteonecrosis of the jaw OR osteonecrosis of the jaw OR dead jaw bone
OR bisphosphonate-related osteonecrosis of the jaw).
2.4. Filters: English
This search was conducted in April 2018 and all hits were imported
into www.covidence.org for screening and reading. The complete search
was performed once per week until 30 April 2019; all new hits were
imported into Covidence for screening.
2.5. Study selection
Two review authors (C.O. and K.G.) independently assessed the
studies for eligibility using Covidence. The studies were assessed first at
the title and abstract level, and later at the full-text level. If no separate
Table 1. Guidelines/Position paper recommendations regarding high-dose antiresorptive drug holidays.
Guideline/Position paper Country Year Recommendations regarding high-dose
antiresorptive drug holidays
Canadian Consensus of Practice Guidelines
for Bisphosphonate Associated
Osteonecrosis of the Jaw [7]
Canada 2008 Urgent invasive oral surgery:
Discontinuation of BP therapy during
healing period, if the medical conditions
permits. Non-emergent procedure: BP
drugs holiday for 3 to 6 months prior to
oral surgery and until complete healing.
Osteonecrosis of the jaw complicating
bisphosphonate treatment for bone disease
in multiple myeloma: an overview with
recommendations for prevention and
treatment [8]
Australia 2009 If the patient's risk of skeletal-related
events is low or intermediate: BP cessation
for 2–3 months before extraction until
complete healing.
The use of bisphosphonates in multiple
myeloma: recommendations of an expert
panel on behalf of the European Myeloma
Network [16]
Europe 2009 Temporary suspension of BP treatment
should be considered if invasive dental
procedures are necessary, but any decision
to suspend BP treatment should be
considered on a case-by-case basis.
Management of patients at risk of
bisphosphonate osteonecrosis in
maxillofacial surgery units in the UK [17]
UK 2009 The use of BPs must be discussed with the
prescribing physician. If continued BP use,
any surgical treatment should be
undertaken with at least a 2 weeks gap
before the next treatment.
Managing the care of patients receiving
antiresorptive therapy for prevention and
treatment of osteonecrosis. Executive
summary of recommendations from the
American Dental Association Council on
Scientific Affairs [9]
USA 2011 Drug holiday from AR drug therapy, or
waiting periods before performing dental
treatment, for prevention of MRONJ.
Guidelines for supportive care in multiple
myeloma 2011 [10]
UK 2011 If the patient's fracture risks and disease
status permits, it seems reasonable to stop
the AR treatment and not recommence
treatment until healing has occured.
Medication-Related Osteonecrosis of the
Jaw - 2014 Update [1]
USA 2014 BP discontinuation prior to oral surgery is
based on an evaluation of the individual
patient's data. If MRONJ, the oncologist
may consider a drug holiday until soft
tissue closure. No studies support or refute
the strategy of stopping Dmab in the
prevention or treatment of MRONJ.
Diagnosis and Management of
Osteonecrosis of the Jaw: A systematic
review and International Consensus [11]
Canada 2014 Drug holiday after oral surgery and until
complete soft tissue healing has occurred.
Medication Related Osteonecrosis of the
Jaw: 2015 Position Statement of the
Korean Society for Bone and Mineral
Research and the Korean Association of
Oral and Maxillofacial Surgeons [14]
Korea 2015 No definite conclusion is made regarding
drug holiday. Only if MRONJ is present,
the necessity of a drug holiday is clear.
"Positionspapier zur
medikamentenassoziierten Osteonekrose
des Kiefers (MRONJ)" [12]
Germany 2016 A 2 months drug holiday before oral
surgery is recommended. If Dmab, the
discontinuation can be shorter.
Resumption when complete healing has
occurred.
Antiresorptive agent-related osteonecrosis
of the jaw: Position Paper 2017 of the
Japanese Allied Committee on
Osteonecrosis of the Jaw [15]
Japan 2016 No consensus regarding drug holiday
before invasive dental treatment. The
decision on whether to implement a
postoperative drug holiday should be made
jointly by the physician and dentist based
on fracture risk. Resumption of BP from 2
weeks to 2 months postoperatively.
Standard Operation Procedure,
Medication-related Osteonecrosis of the
Jaws (Not published)
Denmark 2016 The oncologist discontinues the ARs before
referral to the oral surgeons.
Case-Based Review of Osteonecrosis of the
Jaw (ONJ) and Application of the
International Recommendations for
Management From the International Task
Force on ONJ [13]
Canada 2017 Interruption of BP or Dmab therapy is
advised, if possible before oral surgery and
until soft tissue healing has occurred. The
treatment plan must be individualized for
each patient.
Oral Health Management of Patients at
Risk of Medication-related Osteonecrosis of
the Jaw [18]
Scotland 2017 Drug holidays to avoid the risk of MRONJ
associated with dental care are not
recommended.
AR: Antiresorptive; BP: Bisphosphonate; MRONJ: Medication-related osteonecrosis of the jaw; Dmab: Denosumab.
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Figure 1. Flowchart showing the electronic and manual search results. Abbreviation: n, number of studies.
C. Ottesen et al. Heliyon 6 (2020) e03795abstract was available, the full-text article including the abstract was
used. The level of agreement between the reviewers evaluating abstracts
for inclusion was assessed using Cohen's kappa coefficient [21].
All abstracts referring to an AR drug holiday (e.g., cessation or
discontinuation) were included in the full-text screening to ensure
important points of view regarding the intervention were not overlooked.
The final decision on whether to include a study was always made at the
full-text level. Any disagreements were resolved by discussion between
the two review authors.2.6. Data extraction
The following data items were collected from each literature source:
Authors, year of publication, study design, study intervention, number of
patients, primary diseases, type and duration of antiresorptive treatment,
number of patients in drug holiday, duration of drug holiday, authors’
suggested drug holiday recommendations, development of medication-
related osteonecrosis of the jaw, medication-related osteonecrosis of
the jaw stages, reason for medication-related osteonecrosis of the jaw,
treatment of medication-related osteonecrosis of the jaw and the follow-
up period.2.7. Risk of bias assessment
Bias within the included studies was assessed using the New-
castle–Ottawa Scale (NOS) [22]. The NOS is a quality assessment tool for
non-randomized studies (cohort studies and case-control studies); it
ranks studies by assigning 1 to 9 stars for each quality item defined in
three domains: Selection, Comparability, Outcome/Exposure [22]. The
number of stars are an expression of the quality of the study. The more
stars, the lower the risk of bias. The NOS assessments can be converted
into the more frequently used AHRQ standards (Agency for Healthcare4Research and Quality standard assessments), which include good, fair, or
poor quality depending on number of stars in each NOS domain [37].
3. Results
3.1. Study characteristics
A total of 465 articles were identified from the preliminary electronic
literature search. After duplicates were removed, 371 articles were
screened on the basis of their titles and abstracts (kappa value ¼ 0.89).
Among these, 43 full-text articles were critically reviewed and 5 were
identified as relevant. Nine additional studies, identified by hand-
searching in the text and reference list of the identified literature, were
also included (Figure 1). All 14 included studies were published in
journals registered in either Medline (PubMed), Embase or Cochrane
register.3.2. Description of included studies
A total of 14 studies were included. Among these, three were pro-
spective studies [23, 24, 25] and 11 were retrospective studies [26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36]. Descriptive data, including detailed
study characteristics such as patient population, ARs, AR treatment
duration, MRONJ characteristics, drug holiday characteristics, and au-
thors’ conclusions on drug holidays from the 14 studies fulfilling the
inclusion criteria are presented in Tables 2, 3, and 4.3.3. Methodological quality assessment
The included studies were quality assessed using the NOS (Table 5).
Only one study was awarded 9/9 stars (range: 3–9) [25]. When con-
verting the NOS to the AHRQ standards [37], 4 studies were of good
Table 2. Descriptive characteristics of prospective studies.
Author, Year Design Intervention Patient
population
Primary
disease
Location Type of AR Duration
of AR
(months)
Drug holiday
(patients)
Duration
of drug holiday
(months)
Development
of MRONJ
Authors'
conclusions on
drug holidays
Follow-up
(months)
Saia et al., 2010
[23]
Prospective non-
controlled
cohort study
Surgical tooth
extraction
60 patients/total
of 185 teeth
Metastatic bone
disease, multiple
myeloma or
nonmalignant
bone disease
103 teeth
(55.7%) in the
mandible, 82
teeth (44.3%) in
the maxilla
Zoledronate
(63%),
Pamidronate
(40%),
Neridronate
(7%),
Risedronate
(3%)*
- All 60 patients
paused their BP
therapy
1 to >3 from the
day of surgery
5/60
(all cancer
patients)
Resumption of
BP treatment
was not
associated with
BRONJ
12
Ferlito et al.,
2011 [24]
Longitudinal
observational non-
controlled
cohort study
Evaluate the
time to bony
sequestrum
formation in
patients with
confirmed
MRONJ
94 - - Zoledronate
(77%),
Alendronate
(17%),
Neridronate
(4%),
Ibandronate
(1%), Clodronate
(1%)
1–24þ 43 <6–24 94 (All from
study start)
Suspension of
ARs was
determined by
the clinical
condition of the
patient. Bony
sequestra were
prolonged in
patients
continuing BP
therapy.
Discontinuation
not
recommended
because the
patient may
develop systemic
complications,
such as a
recurrence of
pain or
progression of
the underlying
disease
6
Bodem et al.,
2015 [25]
Prospective
cohort study
Surgical tooth
extraction
61 patients/102
extraction sites/total
of 184 teeth
Breast cancer
(38.9%),
Multiple
myeloma
(17.6%),
Prostatic cancer
(9.25%), Other
(19.4%)
55 teeth (53.9%)
in the maxilla, 47
teeth (46.1%) in
the mandible
Zoledronic acid
(62.4%),
Ibandronate
(28.3%),
Pamidronate
(9.3%)
40.25 (Range
4–245)
17 patients
paused or
completed their
BP therapy at the
time of surgery
17.6  15.9
(range, 1–63)
before surgery
1/17 developed MRONJ
(þDH), 7/44
developed
MRONJ (no DH)
Drug holidays
should not be
implemented for
i.v. BP therapy
3
AAOMS: American Association of Oral and Maxillofacial Surgeons; AR: Antiresorptive; BP: Bisphosphonate; BRONJ: Bisphosphonate induced osteonecrosis of the jaw; DH: Drug holiday; i.v.: Intravenous; MRONJ:
Medication-related osteonecrosis of the jaw; -: Not described in the article.
* percentages >100% as described in the publication by Saia et al.
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Table 3. Descriptive characteristics of retrospective studies.
Study Design Aim No. of patients AR treatment Duration of
AR treatment
(months)
Reasons for
MRONJ
MRONJ stages Treatment of
MRONJ
Dimitrakopoulos
et al., 2006 [36]
Case series >5 Clinical
evaluation of
drug-induced
avascular
osteonecrosis
11 Zoledronate (6/
11), Zoledronate
þ Pamidronate
(4/11),
Pamidronate þ
Ibandronate þ
Zoledronate (1/
11)
6–60 Tooth extraction
(7/11), Chronic
denture trauma
(1/11),
Spontaneous
onset (3/11)
- Sequestrectomy
(3/11),
Debridement (6/
11), No surgical
treatment (2/11)
Wilde et al.,
2011 [27]
Retrospective
cohort study
Surgical
treatment with
bilayer mucosal
closure
24 (33 sites) Zoledronate (14/
24), Zoledronate
þ Bondronate
(3/24),
Zoledronate þ
Pamidronate (3/
34), All three
types of BP (4/
24)
- Misfitting
dentures (6/24),
Extraction (19/
24), Incision
after abscess (1/
24), Periodontal
disease (2/24),
Other (1/24)
1 (2/24), 2 (7/
24), 3 (11/24),
4* (4/24)
All surgically
treated
Jabbour et al.,
2012 [29]
Retrospective
cohort study
Investigating
outcomes of
conservative
therapy alone or
followed by
surgical
treatment
14 Alendronate (4/
14),
Pamidronate (2/
14), Zoledronic
acid (7/14),
Pamidronate þ
Zoledronic acid
(1/14)
12–96 Misfitting
dentures (4/14),
Extractions (7/
14),
Spontaneous
onset (1/14),
Other (1/14),
Not available (1/
14)
2 (14/14) Conservative
treatment (8/
14), Surgical
treatment (6/14)
Voss et al., 2012
[30]
Retrospective
cohort study
Surgical three-
layered
technique
20 (manuscript
describes 21, but
only 20 in the
summary table)
Ibandronate (2/
20), Zoledronate
(14/20),
Alendronate (3/
20),
Pamidronate þ
Alendronate þ
Zoledronate (1/
20)
40.1 (mean)
(range, 6–84)
Extractions (12/
20), Other (8/
20)
2 (15/20), 3 (5/
20)
All surgically
treated
Wutzl et al.,
2012 [26]
Retrospective
analysis of a
prospective
cohort study
Surgery:
therapeutic
approach
41 Pamidronate (7/
41), Zoledronic
acid (25/41),
Zoledonric acid
þ other
bisphosphonate
(8/41),
Alendronate (1/
41)
- - 0 (1/41), 1 (10/
41), 2 (24/41), 3
(6/41)
All surgically
treated
Kim et al., 2014
[31]
Retrospective
cohort study
Investigating
prognostic
factors after
surgical
management of
patients
diagnosed with
MRONJ
54 Alendronate
(35/54),
Risedronate (9/
54), Ibandronate
(3/54),
Pamidronate (4/
54),
Surgical
treatment: 54
(mean);
Conservative
treatment: 86
(mean)
Extraction of
teeth (33/54),
Implant (4/54),
Curettage (1/
54), Partial
dentures (2/54),
Spontaneous
0 (4/54), 1 (17/
54), 2 (32/54), 3
(1/54)
Surgically
treated with
debridement or
sequestrectomy
(21/54),
Conservatively
treated (33/54)
(continued on next page)
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Table 3 (continued )
Study Design Aim No. of patients AR treatment Duration of
AR treatment
(months)
Reasons for
MRONJ
MRONJ stages Treatment of
MRONJ
Zolendronate (4/
54)y
onset (6/54), No
data (8/54)
Lopes et al.,
2015 [32]
Retrospective
observational
cohort study
Evaluation of the
efficacy of
surgery
33 (46 sites) Zoledronate (22/
33),
Pamidronate (3/
33), Zoledronate
þ Pamidronate
(5/33),
Alendronate (2/
33), Zoledronate
þ Alendronate
(1/33)
I.v. treatment:
26.3 (mean) (2
patients with
Alendronate for
10 years)
Extractions (16/
33), Implant
treatment (3/
33), Periodontal
disease (9/33),
Misfitting
dentures (8/33),
Palatal tori (2/
33),
Spontaneous
onset (8/33)
2 (37/46), 3 (9/
46)
All surgically
treated
Bodem et al.,
2016 [33]
Monocentric
retrospective
cohort study
Analysis of
surgical
outcomes: i.e.,
drug holiday
versus no drug
holiday
39 (47 sites) Zoledronic acid
(39/39)
24 (range 2–120) - 2 (23/47), 3 (24/
47)
All surgically
treated
Hoefert et al.,
2017 [34]
Retrospective
review of
medical records
Examination of
clinical
characteristics
and operative
and non-
operative
therapeutic
outcomes
17 XGEVA (15),
Prolia (2)
19.7  10.5
(range 4–48)
Misfitting
dentures (7/17),
Extractions (6/
17), Peri-
implantitis (1/
17),
Periodontitis (2/
17),
Spontaneous
onset (1/17)
1 (1/17), 2 (10/
17), 3 (6/17)
Operative (7/
17), Non-
operative (10/
17)
Aljohani et al.,
2018 [35]
Retrospective
multicenter case
series
Analysis of AR
characteristics,
demographics,
related
comorbidities,
local preceding
events,
treatment
strategies, and
treatment
outcomes.
63 XGEVA (52/63),
Prolia (11/63)
(31/63 patients
had a history of
bisphosphonate
use)
- Extractions (28/
63),
Periodontitis (6/
63), Misfitting
dentures (4/63),
Implant
placement (2/
63), Peri-
implantitis (1/
63), Other (9/
63), Unknown
(13/63)
0 (2/63) 1 (6/
63) 2 (41/63) 3
(8/63)
Combined (6/
63)
Surgical (60/
63), Non-
surgical (3/63)
Jung et al., 2018
[28]
Retrospective
cross-sectional
study (database)
Investigation of
the gap between
BP use and the
occurrence of
MRONJ.
1569 Alendronate,
Clodronate,
Etidronate,
Ibandronate,
Risedronate,
Pamidronate,
Zoledronic acid
2.94 years
(average)
Dental surgery,
including
extractions
(915/1,569)
- -
AR: Antiresorptive; MRONJ: Medication-related osteonecrosis of the jaw; i.v.: Intravenous.
* Stage 4 is defined in this study; -: Not described in the article.
y This may be an error in the original article because n ¼ 55, not 54 as described.
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Table 4. Drug holiday recommendations from the retrospective studies.
Study Primary disease Drug holiday (patients)* Duration of drug
holiday (months)
Healing of MRONJ
(patients with drug holidays)
Authors' conclusions
on drug holidays
Dimitrakopoulos et al., 2006 [36] Breast cancer (1/11), Prostate
cancer (2/11), Multiple myeloma
(5/11), Neuroendocrine cancer
(1/11), Lung cancer (1/11),
Fibrous dysplasia (1/11)
10/11 2–8 5/10 Discontinuation of BP, combined
with surgical debridement, is the
treatment of choice. More than 3
months of cessation appears to be
necessary
Wilde et al., 2011 [27] Breast cancer (6/24), Prostate
cancer (7/24), Multiple myeloma
(7/24), Thyroid cancer (1/24),
Hodgkin's lymphoma (1/24), Non-
Hodgkin's lymphoma (1/24),
Kidney cancer (1/24)
10/24 - 10/10 Treatment results were not
significantly affected, whether BP
therapy was continued or
discontinued. The results of this
study indicate that there is no
reason to interrupt AR therapy for
surgery
Jabbour et al., 2012 [29] Osteoporosis (4/14), Breast cancer
(5/14), Prostate cancer (2/14),
Multiple myeloma (1/14), Kidney
cancer (2/14),
9/14 (7 with cancer) - 10/14 There was no standard protocol
for a drug holiday in this study.
None of the patients died or had
their health status changed due to
discontinuation of BP therapy
Voss et al., 2012 [30] Osteoporosis (4/20), Breast cancer
(9/20), Prostate cancer (1/20),
Thyroid cancer (1/20),
Plasmacytoma (3/20), Vulva
cancer (1/20), Kidney cancer (1/
20)
20/20 1–1.5 (4 weeks before, 6 weeks
after)
19/20 An individual approach in
consultation with the prescribing
oncologist is recommended
Wutzl et al., 2012 [26] Osteoporosis (5/41), Breast cancer
(9/41), Prostate cancer (3/41),
Multiple myeloma (20/41),
Histiocytosis X (1/41), Lung
cancer (2/41), Anal cancer (1/41)
28/41 ?–6 (6 post-operatively) - Discontinuation of BPs before
surgery favored significantly
better treatment outcomes
Kim et al., 2014 [31] Osteoporosis (47/54), Breast
cancer (1/54), Multiple myeloma
(5/54), Malignant lymphoma (1/
54)
54/54 Surgical treatment group: 6.9
Conservative treatment group: 7.2
11/20 A correlation was found between
drug holidays and prognoses in the
surgical treatment group. Drug
holiday durations should be at
least 4 months to prevent a poor
prognosis after surgical
management
Lopes et al., 2015 [32] Osteoporosis (2/33), Breast cancer
(18/33), Prostate cancer (4/33),
Multiple myeloma (4/33), Lung
cancer (4/33), Kidney cancer (1/
33)
31/33 6.8  9.2 - A total of 40/46 sites (87%)
healed. No conclusions can be
drawn from this study
Bodem et al., 2016 [33] Malignant disease (39/39) 15/39 - 9/15 showed complete healing, 4/
15 showed relative healing 2/15
showed no healing
No statistically significant
differences were observed
between patients who were still
receiving their i.v. BPs at the time
of surgery and those on a drug
holiday
Hoefert et al., 2017 [34] Osteoporosis (1/17), Breast cancer
(9/17), Prostate cancer (6/17),
Lung cancer (1/17)
10/17 - 5/10 Cessation of denosumab treatment
had no apparent effect on healing
outcomes
Aljohani et al., 2018 [35] Osteoporosis (9/63), Breast cancer
(27/63), Prostate cancer (17/63),
Multiple myeloma (2/63), Lung
42/63 6  3.4 Healing (5/42), Partial healing (3/
42), No healing (5/42), Missing
data (9/42)
No associations were observed
between denosumab drug
holidays and healing outcomes
(continued on next page)
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9quality [23, 24, 25, 26], 8 studies were of fair quality [27, 28, 29, 30, 31,
32, 33, 34] and 2 studies were of poor quality [35, 36].
3.4. Outcomes: prospective studies
Of all the included studies, only the one performed by Bodem et al.
fitted the PICO framework (25). This was the only study with surgical
tooth extraction as the intervention and a related BP drug holiday, which
included a control group.
Bodem et al. investigated whether patients undergoing i.v. BP treat-
ment during surgery had a higher risk of BP-related osteonecrosis of the
jaw (BRONJ) than patients who had a drug holiday, i.e., patients who had
completed their BP treatment or had it temporarily suspended. A total of
17 of 61 patients had their high-dose AR therapy temporarily suspended
prior to tooth extraction. Only 1 of the 17 patients developed MRONJ
(5.9%). In total, 7 of the 44 patients in the control group developed
MRONJ (16%) No significant differences were found (p ¼ 0.4232) [25].
In the study by Saia et al., BP therapy was discontinued at the time of
surgical tooth extractions, and all patients discontinued the AR treatment.
The majority of the patients restarted BP treatment 1 month after the ex-
tractions. The objective was to reduce BP accumulation in the alveolar
sockets. Six patients discontinued theAR therapy for a longer perioddue to
the presence of osteomyelitis in bone biopsies, and 2 of these 6 patients
restarted the therapy 3months later due to metastatic progression. In this
study, resumption of BP treatment was not associated with BRONJ 12
monthsafter toothextraction.TheincidenceofMRONJinthis study,which
included a drug holiday, was 5 of the 60 patients (8.3%) [23].
The final prospective study that was included described a protocol for
treating BRONJ [24]. In this study by Ferlito et al., all patients had
BRONJ diagnosed from the start of the study. In total, 43 of 94 patients
had drug holidays of differing durations. The authors found that pro-
longed bone sequestration occurred in patients continuing BP therapy,
because the last patient to develop a sequestrum had continued treatment
with zoledronate. However, these authors did not recommend drug
holidays [24].
None of the prospective studies involved a denosumab drug holiday.
3.5. Outcomes: retrospective studies
None of the 11 retrospective studies that were included fitted the
PICO framework, but all of them drew conclusions on drug holidays.
Patients were receiving denosumab therapy in 2 of the 11 studies [34,
35]. Drug holidays were recommended in 3 studies [26, 30, 35], whereas
3 studies found no reason to discontinue treatment [27, 33, 34] and 5
studies suggested drug holidays should be considered on a case-by-case
basis (Table 4) [28, 29, 31, 32, 36]. Only in the study by Voss et al. a
detailed drug holiday description was given, high-dose AR was paused 4
weeks before operation and restarted 6 weeks postoperatively [30].
Most of the retrospective studies were mixed studies, meaning that
the patient population was a mixture of patients in high-dose AR treat-
ment (cancer patients) and low-dose AR treatment (osteoporotic pa-
tients). The one retrospective study that included only patients diagnosed
with a malignant disease was that performed by Bodem et al. [32].This
study analyzed the surgical outcomes for 39 patients with malignant
diseases who received high-dose zoledronic acid treatment and had
established BRONJ. At the time of surgical resection, 15 patients were
registered as having a drug holiday. No statistically significant differ-
ences for healing after surgery were observed between patients under-
going ongoing BP therapy and those with temporarily
suspended/completed BP therapy.
4. Discussion
In this systematic review, we investigated the evidence and efficacy of
a high-dose AR drug holiday. Only one prospective study with a control
group fitted the PICO framework, and this study concluded that drug
Table 5. Quality assessment of studies (Newcastle-Ottawa Scale).
Reference Selection Comparability Outcome
Was the exposed
cohort representative?
Selection of
the non-exposed
cohort
Ascertainment of
exposure
Demonstration that
outcome of interest
was
not present at
start of study
Comparability of cohorts
on the basis of the design
or analysis
Assessment
of outcome
Was follow-up long
enough for
outcomes to occur
Adequacy of
follow up of cohorts
Overall quality
assessment
NOS score (0–9)
J.P Bodem et al.,
2015 [25]
* Truly representative of
typical patients being
treated with high-dose
ARs in the community.
* Drawn from the
same community as
the exposed cohort
* Secure record * Yes * Study controls for
ongoing vs. completed/
paused therapy.
*Study controls for
additional factors
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
9
G. Saia et al.,
2010 [23]
* Truly representative of
typical patients being
treated with high-dose
ARs in the community.
No description * Secure record * Yes * Study controls for
additional factors
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Ferlito et al.,
2011 [24]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record * Yes * Study controls for type
of bisphosphonates
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Dimitrakopoulos
et al., 2006 [36]
Selected group of users. No description * Secure record No - * Independent assessment * Yes * Complete follow up
- all subjects
accounted for
3
Wilde et al.,
2011 [27]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No * Study controls for
patients' generel health
status.
*Study controls for
additional factors
* Independent assessment * Yes * 37.5% lost to
follow-up,
description provided
of those lost
4
Jabbour et al.,
2012 [29]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No - * Independent assessment * Yes * Complete follow up
- all subjects
accounted for
5
Voss et al., 2012
[30]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No * Study controls for
duration of
bisphosphonates.
*Study controls for
additional factors
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Wutzl et al.,
2012 [26]
* Truly representative of
typical patients being
treated with high-dose
ARs in the community.
No description * Secure record * Yes * Study controls for the
effect of continuing
therapy with
bisphosphonates.
*Study controls for
additional factors.
* Independent assessment * Yes * 15% lost to follow-
up, but unlikely to
produce bias
8
Kim et al., 2014
[31]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No * Study controls for drug
holiday.
*Study controls for
additional factors.
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Lopes et al.,
2015 [32]
* Somewhat
representative of typical
patients being treated
No description * Secure record No - * Independent assessment * Yes * 61% lost to follow
up. Descriptions
provided for the
5
(continued on next page)
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Table 5 (continued )
Reference Selection Comparability Outcome
Was the exposed
cohort representative?
Selection of
the non-exposed
cohort
Ascertainment of
exposure
Demonstration that
outcome of interest
was
not present at
start of study
Comparability of cohorts
on the basis of the design
or analysis
Assessment
of outcome
Was follow-up long
enough for
outcomes to occur
Adequacy of
follow up of cohorts
Overall quality
assessment
NOS score (0–9)
with high-dose ARs in the
community.
subjects who could
not be followed up.
Bodem et al.,
2016 [33]
* Truly representative of
typical patients being
treated with high-dose
ARs in the community.
No description * Secure record No * Study controls for drug
holidays. *Study controls
for additional factors.
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Hoefert et al.,
2017 [34]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No * Study controls for the
duration of therapy.
*Study controls for
additional factors.
* Independent assessment * Yes * Complete follow up
- all subjects
accounted for
7
Aljohani et al.,
2018 [35]
* Truly representative of
typical patients being
treated with high-dose
ARs in the community.
No description * Secure record No * Study controls for
denosumab dose.
*Study controls for
additional factors.
* Independent assessment * Yes 17% lost to follow-
up. No descriptions
of the subjects who
could not be followed
up.
6
Jung et al., 2018
[28]
* Somewhat
representative of typical
patients being treated
with high-dose ARs in the
community.
No description * Secure record No * Study controls for drug
holidays.
*Study controls for
additional factors.
* Independent assessment No statement No statement 4
AR: Antiresorptive.
* One star is awarded for each item, with a maximum of two stars being awarded for comparability; -: Not described in the article.
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C. Ottesen et al. Heliyon 6 (2020) e03795holidays should not be implemented for i.v. BP therapy [25]. Thus, based
on this study the hypothesis should be rejected. Drug holiday of
high-dose AR will not reduce the risk of MRONJ. However, it would be
wrong only to make this conclusion based on one underpowered, pro-
spective controlled study. Although the other included studies did not
directly compare discontinuation with continuation of high-dose AR
therapy, they draw conclusions on implementing drug holidays based on
different observations. It is clear that the level of evidence was low, but
represents the best available information on this subject. None of the
studies were randomized and most of them had a relatively small sample
size, resulting in low-grade scientific evidence. Although identifying an
important research question is relatively straightforward, the low inci-
dence of MRONJ and high variation among patients and AR therapies
mean it is difficult to complete RCTs or controlled prospective studies
with sufficient patient numbers to answer that question. Even relevant
low-level evidence studies are difficult to perform and should be
respected for the accumulation of knowledge within this difficult to reach
subject area. Consequently, some of these studies were mixed (e.g.,
including patients undergoing both high-dose and low-dose AR therapy).
This is clearly one of the limitations of this review, because most of the
included studies did not exclude patients undergoing low-dose AR
treatment (e.g., patients with osteoporosis). Nevertheless, these studies
are important and must be analyzed to understand the reasons for
implementing high-dose AR drug holidays. Another limitation is related
to the search strategy with MeSH terms and free text, where only 5
studies were identified. Thus, 9 studies were added through other sour-
ces. This was mainly due to the limited size of the topic and the great
variation in used text words.
In the prospective studies by Bodem et al. and Saia et al., the number
of patients and the surgical techniques were similar. Most patients in the
two studies were undergoing high-dose BP treatment, but the health
status of the patients varied, which also is a limitation difficult to avoid.
In the study by Bodem et al., all the patients had been diagnosed with
metastatic bone cancer, which means that the health of these patients
had been compromised compared to patients who did not have cancer
(e.g., patients diagnosed with osteoporosis) [25]. A compromised im-
mune response may increase susceptibility to infections and possibly
MRONJ onset [16]. In the study by Saia et al., only 72% of the patients
were diagnosed with cancer [23].
The specific ARs used may be important for any relationship between
drug holidays and MRONJ development. Although all AR agents modify
bone remodeling by inducing apoptosis and inhibiting osteoclast medi-
ated bone resorption, BPs and denosumab behave differently.
There are different types of BPs; all have a high affinity for bone, but
their binding strengths are different. BPs have half-lives of approximately
10–12 years and continue to be recycled when bone is remodeled [38,
39].
Denosumab is a more recently developed AR agent, which is also used
frequently. Denosumab is a humanmonoclonal antibody directed against
the receptor activator of nuclear factor kappa B ligand (RANKL) [38].
RANKL is a membrane protein expressed in several tissues and organs.
Denosumab targets osteoclast precursor cells in the bone marrow and
also functions in bone tissue, where it stops osteoclast precursor cells
from differentiating into mature osteoclast cells, as well as inhibiting the
function and survival of existing osteoclasts. Denosumab has a half-life of
25.4 days, which means a single dose is reduced to an insignificant level
after approximately 4–6 months [38].
The effects of BP and denosumab drug holidays may be very different,
due to the different pharmacokinetic properties of the two agents. A BP
drug holiday may be ineffective, due to the long half-life of the drugs. BPs
will remain in the bone for years after patients have stopped receiving
them. A temporary discontinuation of denosumab could be favorable due
to denosumab's short half-life [40] – but an AR drug holiday may also
increase the risk of SREs including recurrence of bone pain and possibly
progression of bone metastases in the patients [41, 42, 43, 44]. When12compared with zoledronic acid in a phase 3 trial, denosumab was asso-
ciated with an increased rate of progression-free survival [43].
Patients were receiving denosumab therapy in only 2 of the 14 studies
that were included [33, 34]. Hoefert et al. described data from 17 pa-
tients who underwent denosumab therapy. In total, 15 of these patients
had high-doses of denosumab (Xgeva), but only 6 of the 17 patients had
tooth extractions prior to MRONJ onset. However, in this study, the
authors concluded that a denosumab drug holiday seemed to have no
effect on healing outcomes and MRONJ onset [33]. Aljohani et al. also
found no association between a denosumab holiday and MRONJ healing
among 63 patients. In total, 49 of the 63 patients were treated using
high-doses of Xgeva, and tooth extraction was the reason for MRONJ
onset in 28 patients [34]. Thus, neither of the denosumab studies found
that a drug holiday had any effect.
The remaining 12 studies, including the 3 prospective studies,
involved BPs and only 2 of these studies clearly indicated that AR therapy
should not be interrupted [25, 27]. Wilde et al. reported a retrospective
study of 24 patients with a surgical aspect, which included resection of all
necrotic bone, smoothing sharp bone edges, and primary wound closure.
In total, 10 patients discontinued their BP therapy after being diagnosed
with MRONJ. The authors observed no treatment failures within this
group of patients, but among the 14 patients that continued their BP
therapy, treatment was unsuccessful in four cases. However, the authors
found no significant relationship between continued BP therapy and
treatment failure, and they concluded that the results of the investigation
did not support discontinuing BP therapy to perform surgery [27].
The remaining 10 studies recommended discontinuing BP therapy,
suggested making decisions on a case-by-case basis with no standard
protocol for drug holidays, or reported no conclusions regarding drug
holidays at the time of tooth extraction.
Three retrospective studies found that a drug holiday for oral surgery
was beneficial [26, 30, 35]. All patients in these retrospective studies had
a MRONJ diagnosis at the time of the drug holidays. All 3 studies
concluded that discontinuing BP therapy for more than 3 months had a
positive effect on surgical outcomes. However, in the study performed by
Kim et al., only 7 of the 54 patients had a malignant disease and these
patients were not described as a group [30]. Dimitrakopoulos et al. found
that the oncologist's opinion of the patient's disease status was a crucial
factor in the decision to stop BP therapy for MRONJ treatment [35].
Wutzl et al. stated that the effectiveness of drug holidays, either for
elective oral surgery or therapeutic reasons, should be assessed by future
controlled studies [26]. These findings are consistent with some existing
position papers and guidelines [7, 8, 9, 10, 11, 12, 13], whereas others
suggest continuing drug therapy or making decisions on a case-by-case
basis [1, 14, 15, 16, 17, 18].
Most of the studies included in this systematic review did not give any
detailed description of the use of drug holidays (e.g. how long preoper-
atively, how long postoperatively) and did not draw specific conclusions
on drug holidays either, but recommended assessing each case separately
–most often in close collaboration with the physician [24, 28, 29, 31, 32,
36]. In the study performed by Voss et al., all patients discontinued their
BP medication 4 weeks before and 6 weeks after surgery. This is the most
details description of the use of drug holiday. These authors recom-
mended early surgery because many oncologists discontinue
BP-treatment once the patient develops exposed bone, to promote wound
healing. However, there is a risk of pathological fractures and/or pro-
gression of the underlying disease due to the drug holiday [29]. In the
study described by Jabbour et al., temporary discontinuation of BP
therapy was discussed with the specialist responsible for treatment.
However, the most recent follow-up to this study found that drug holi-
days had not apparently changed the health status of any of the patients
[28]. Bodem et al. investigated whether patients who were undergoing
i.v. BP therapy at the time of surgery had a higher risk of treatment
failure compared with patients who had completed their BP therapy or
had it temporarily suspended. This retrospective cohort study included a
total of 39 patients with cancer. At the time of surgery, 15 patients
C. Ottesen et al. Heliyon 6 (2020) e03795(31.9%) were registered as having a drug holiday. In total, 9 of these 15
patients (60%) showed complete healing, but these findings were not
statistically significant [32]. These results contrast with those reported
by Wutzl et al. [26]; although, this may be because Wutzl et al. did not
have a homogeneous study population. Jung et al. investigated the
relationship between BP treatment and the occurrence of ONJ using a
national database. A total of 1,569 patients were included based on
4-years retrospective periods, and only 317 patients were being treated
with high-dose BP therapy. The authors found that 53.3% of all in-
cidences of ONJ during the study period occurred after a drug holiday
and that the frequency of ONJ occurrence declined steadily as the length
of the drug holidays increased [36].
As with many similar studies, a limitation of the research performed
by Jung et al. was that the study population was not homogeneous. In
addition, many of these studies do not include patients who do not have
MRONJ, and few studies compare drug holidays against no drug holi-
days. For example, Saia et al. reported that all patients included in their
prospective cohort study had a drug holiday, meaning that no compari-
son was made between a drug holiday and “no drug holiday”. In the study
by Bodem et al., only 17 patients had their BP treatment temporarily
suspended; one of these patients developed MRONJ [25]. Saia et al. re-
ported that 5 of their 44 cancer patients developed MRONJ. However,
the AR agent treatment durations were not described [23]. Given the
strong correlation between AR treatment duration and the risk of
MRONJ, this is a limitation of the study performed by Saia et al.
Usually, the decision on whether to implement a drug holiday is taken
by the oncologist and maxillofacial surgeon in close collaboration. The
oncologist's decision is based on how healthy each patient is, and this is
considered the internationally accepted procedure.
4.1. Expert opinion
The question whether to pause high-dose antiresorptive therapy in
cancer patients when tooth extraction is needed is a worldwide concern.
To date, there do not exist any high-evidence trials that give us infor-
mation about this question. To fill out the gap of knowledge about high-
dose drug holiday, we have designed a single-blinded randomized
controlled trial, which aim is to evaluate high-dose antiresorptive drug
holiday related to tooth extraction with primary mucosal closure in
cancer patients, including how a drug holiday affects the health related
quality of life. A feasibility study of the designed trail is right now
ongoing at the department of Oral & Maxillofacial Surgery, Copenhagen
University Hospital, Denmark. If this study indicate that the study setup
is useful and that there are no clear adverse effects of not using a drug
holiday, additional studies with necessary statistical power should be
initiated.
As previously told, it is gold standard to pause the high-dose anti-
resorptive treatment in relation to tooth extraction in Denmark, like in
many other countries worldwide, even though the lack of evidence. If our
clinical trial reveals that a drug holiday is not necessary to avoid the
development of MRONJ, it will have high impact on how to treat the
oncological patients in the future. If cancer patients can continue their
antiresorptive therapy, and thus the potential good effect on controlling
metastatic progression and skeletal related pain, it will certainly benefit
the patients. We hope that our randomized trial will contribute to answer
the question whether to use or not to use high-dose drug holiday in
relation to tooth extraction.
5. Conclusions
The efficacy of a high-dose AR drug holiday remains uncertain.
Applying the PICO approach suggests that the focused question cannot be
answered using high-level evidence, because no RCTs and only one
controlled prospective study were identified. This study indicated that
drug holiday of high-dose ARwill not reduce the risk of MRONJ andmust
therefore be seen as unnecessary. Retrospective studies and case-series13without controls suggested that high-dose AR drug holidays could pro-
duce different results. Good quality, large prospective studies may lead to
firmer conclusions, although the unusual outcome and limited numbers
of eligible patients make such studies difficult to perform and complete.
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